SHAN6 (DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)) / Sanofi - LARVOL DELTA

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (clinicaltrials.gov) - P3 | N=250 | Recruiting | Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A Phase 3 Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (clinicaltrials.gov) - P3 | N=250 | Not yet recruiting | Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.

New P3 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Development of active double-layer film from sunflower by-products: A pectin-based system for chicken freshness monitoring and preservation. (PubMed, Carbohydr Polym) - "Finally, the results of chicken breasts wrapped with this film showed that the SP/G/SHAN6%/ZNF/SEO double-layer film not only monitored the freshness of chicken but also extended the shelf life of chicken breasts up to 12 days at 4 °C. Therefore, this intelligent and active double-layer film presented promising applications for effective freshness monitoring and food preservation."

Journal

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections • Pediatrics

MET55: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (clinicaltrials.gov) - P3 | N=1328 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Jan 2023 | Trial primary completion date: Jul 2024 ➔ Jan 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Meningococcal Infections • Pediatrics

MEQ00064: Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (clinicaltrials.gov) - P3 | N=1528 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Meningococcal Infections • Pediatrics

Study of Full Schedule (3-Dose of Shan6™) or Shan6™-Shan5®-Shan6™ Versus the Licensed Vaccine Shan5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants (clinicaltrialsregister.eu) - P3 | N=690 | Sponsor: Sanofi Pasteur

New P3 trial • Dermatology • Infectious Disease

MET55: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (clinicaltrials.gov) - P3 | N=1482 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial completion date: Sep 2023 ➔ Jul 2024 | Trial primary completion date: Sep 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Infectious Disease • Meningococcal Infections

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3 | N=460 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Pertussis • Pneumococcal Infections • Respiratory Diseases • Rotavirus Infections • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) vaccine administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in Thailand (clinicaltrialsregister.eu) - P3 | N=460 | Sponsor: Sanofi Pasteur

New P3 trial • Dermatology • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Pediatrics • Pertussis • Respiratory Diseases • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Active, not recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Pediatrics • Pertussis • Respiratory Diseases • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Trial completion date: Mar 2022 ➔ Dec 2021; Trial primary completion date: Nov 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Pediatrics • Pertussis • Respiratory Diseases • Tetanus

Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian Infants Studio per valutare la risposta immunitaria e il profilo di sicurezza del vaccino combinato DTaP-IPVHB- PRP ~ T somministrato in concomitanza o in sequenza con il vaccino 4CMenB in infanti italiani (clinicaltrialsregister.eu) - P4; N=396; Ongoing; Sponsor: SANOFI PASTEUR

Clinical • New P4 trial • CNS Disorders • Hepatitis B • Infectious Disease • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hepatitis B • Infectious Disease • Pediatrics • Tetanus

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (clinicaltrials.gov) - P3; N=460; Not yet recruiting; Sponsor: Sanofi Pasteur, a Sanofi Company

Clinical • New P3 trial • Hepatitis B • Infectious Disease • Pediatrics • Tetanus

Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine. (PubMed, Pediatr Infect Dis J) - "The safety of DTaP5-HB-IPV-Hib is consistent with the safety profile of its components and similar to comparator vaccines, including INFANRIX hexa. The vaccine provides a new, fully liquid and convenient hexavalent vaccination option for use with various vaccination schedules in Europe."

Clinical • Journal

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (clinicaltrials.gov) - P3; N=53; Completed; Sponsor: Sanofi Pasteur, a Sanofi Company; Active, not recruiting ➔ Completed; N=100 ➔ 53; Trial completion date: Aug 2020 ➔ Feb 2019; Trial primary completion date: Sep 2018 ➔ Feb 2019

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a 2nd Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (clinicaltrialsregister.eu) - P3; N=100; Sponsor: Sanofi Pasteur SA

Clinical • New P3 trial